
|Videos|July 30, 2020
What Aviceda’s lead candidate AVD-104 may mean for dry AMD (ASRS 2020)
Author(s)Alex Delaney-Gesing
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
Advertisement
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, Ophthalmology Times'® group editorial director, during the virtual 2020 American Society of Glaucoma Specialists (ASRS) annual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
PRIMA retinal implant restores vision in patients with advanced GA
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
5














































